A Multicenter, Randomized, Open-label Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With T2 DM With Inadequate Glycemic Control on Metformin.
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Sitagliptin (Primary) ; Antihyperglycaemics; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co
- 10 Jun 2017 Biomarkers information updated
- 20 May 2009 Primary outcome changed from tolerability to, change from baseline in proportion of glycosylated haemoglobin as reported by ClinicalTrials.gov.
- 09 Apr 2009 New trial record